Manipulations of endocannabinoid degradative enzymes (e.g., fatty acid amide hydrolase, monoacylglycerol lipase, and α/β-hydrolase domain-6), CB1 and CB2 receptors, and their endogenous ligands have shown promise in modulating cellular and molecular hallmarks of TBI pathology such as; cell death, excitotoxicity, neuroinflammation, cerebrovascular breakdown, and cell structure and remodeling. TBI-induced behavioral deficits, such as learning and memory, neurological motor impairments, post-traumatic convulsions or seizures, and anxiety also respond to manipulations of the endocannabinoid system.
Link: Endocannabinoids: A Promising Impact For Traumatic Brain Injury
Year: 2017
DOI: 10.3389/fphar.2017.00069
Likely probability of the efficacy of cannabis for treatment of Traumatic Brain Injury according to the results found in this study.
ECS review
Synthetic cannabinoid CT-3, a potent analog of THC-11-oic acid